AlfredGarfallMD
Oncology • Philadelphia, PAHematologic Oncology
Assistant Professor, Department of Medicine, Division of Hematology/Oncology, Perelman School of Medicine, University of Pennsylvania
Dr. Garfall is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Civic Center Blvd
Fl 3
Philadelphia, PA 19104Phone+1 215-615-5858Fax+1 215-615-3349
Summary
- Dr. Alfred Garfall is an oncologist in Philadelphia, PA and is affiliated with multiple hospitals in the area, including Hospital of the University of Pennsylvania. He received his medical degree from NYU School of Medicine and has been in practice 9 years. He specializes in hematologic oncology and is experienced in amyloidosis and multiple myeloma.
Education & Training
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2011 - 2014
Brigham and Women's HospitalResidency, Internal Medicine, 2008 - 2011
New York University School of MedicineClass of 2008
Certifications & Licensure
NJ State Medical License 2022 - 2025
PA State Medical License 2011 - 2024
MA State Medical License 2010 - 2011- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Phase I/II Study of BI-505 in Conjunction With Autologous Stem Cell Transplant in Multiple Myeloma Start of enrollment: 2016 May 01
- CART-19 Post-ASCT for Multiple Myeloma Start of enrollment: 2016 Jun 01
- Up-front CART-BCMA With or Without huCART19 in High-risk Multiple Myeloma Start of enrollment: 2018 May 09
Publications & Presentations
PubMed
- 175 citationsCarfilzomib-Associated Cardiovascular Adverse Events: A Systematic Review and Meta-analysis.Adam Waxman, Suparna C. Clasen, Wei-Ting Hwang, Alfred L. Garfall, Dan T. Vogl
JAMA Oncology. 2017-12-28 - 327 citationsTeclistamab in Relapsed or Refractory Multiple Myeloma.Philippe Moreau, Alfred L Garfall, Niels W C J van de Donk, Hareth Nahi, Jesús F San-Miguel
The New England Journal of Medicine. 2022-08-11 - 51 citationsT cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.Guido Ghilardi, Joseph A Fraietta, James N Gerson, Vivianna M Van Deerlin, Jennifer J D Morrissette
Nature Medicine. 2024-04-01
Abstracts/Posters
- Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell PrecursorsAlfred L Garfall, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Re...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Penn Medicine Awarded $14 Million NIH Grant to Apply CAR T Immunotherapies to Match More Patients in Need of Kidney TransplantsDecember 27th, 2021- Colin Powell’s COVID-19 Death Followed Cancer Diagnosis, TreatmentOctober 21st, 2021
Crossing the Finish LineDecember 3rd, 2019- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
